Startups channel feed

'We want to be every­where.' Mis­sion Bio rais­es $70M be­hind re­sis­tance-hunt­ing se­quenc­ing plat­form

5 years ago
Financing

Per­cep­tive births its first in-house start­up — and it's a Chi­na play

5 years ago
Deals
China

RA Cap­i­tal-backed Aerovate launch­es with $72.6M to treat PAH with a re­pur­posed can­cer med

5 years ago

Ver­sant funds TCR ther­a­py biotech T-knife's $78M+ Se­ries A to boost hu­man­ized T cell mice plat­form

5 years ago
Financing

Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. Is an IPO next?

5 years ago
Financing

Ver­sant de­buts Ridge­line's start­up #4, armed with $30M and al­ter­na­tive TCR cell ther­a­pies for sol­id tu­mors

5 years ago
Financing

IgGenix emerges from stealth with $10 mil­lion Se­ries A hop­ing to re-en­gi­neer al­ler­gic cas­cade

5 years ago
Financing

'Ex­quis­ite con­trol': Flag­ship pulls off $85M ral­ly around Omega Ther­a­peu­tic­s' clin­i­cal push for epi­ge­net­ic pro­gram­ming tech

5 years ago
Financing
Cell/Gene Tx

Three years af­ter leav­ing Bio­gen, Alp­na Seth takes the spot­light with $73M for her neu­ro start­up

5 years ago
Financing

A pro­tein en­gi­neer­ing plat­form spawns a new IL-2 play­er out of Basel, with hu­man tri­als loom­ing next sum­mer

5 years ago
R&D

Suc­cess­ful sci­en­tist-in­vestor al­lies team up again — this time for a stab at rare meta­bol­ic dis­ease

5 years ago
Financing

Christoph West­phal bags a $170M Fund V, slat­ed to help breed some new biotechs at Long­wood

5 years ago
Financing

'Miss­ing link': Bay­er, Morn­ing­side help cat­a­pult a new kind of de­liv­ery tech to cell and gene ther­a­py

5 years ago
Financing
Cell/Gene Tx

Cul­li­nan On­col­o­gy launch­es new sub­sidiary fo­cused on col­la­gen-bind­ing cy­tokine treat­ment

5 years ago

El­e­va­tion On­col­o­gy launch­es with $32.5 mil­lion Se­ries A, gives new life to for­mer Mer­ri­mack pro­gram

5 years ago
Financing

Chris Garabe­di­an's in­cu­ba­tor leads Se­ries A fund­ing for gene ther­a­py man­u­fac­tur­er/de­vel­op­er com­bo

5 years ago
Financing
Cell/Gene Tx

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

5 years ago
Bioregnum
Opinion

New biotech Exalys, seek­ing to pre­vent post­op­er­a­tive delir­i­um, launch­es with $15 mil­lion in Se­ries A

5 years ago
Financing

Af­ter psilo­cy­bin and ke­t­a­mine, a new biotech comes along de­vel­op­ing a drug Scott Got­tlieb fought

5 years ago
R&D
In Focus

Stan­ford star on­col­o­gy sci­en­tist Ed En­gle­man helped cre­ate the im­munother­a­py field. Now he wants to shake up neu­rode­gen­er­a­tion R&D

5 years ago
People
Financing

Flag­ship ex­ecs take a les­son from na­ture to mas­ter ‘gene writ­ing,’ launch­ing a star-stud­ded biotech with big am­bi­tions to cure dis­ease

5 years ago
Cell/Gene Tx

Out of jobs, a pair of ear­ly cell ther­a­py ex­ec­u­tives went to Seoul, came back with a new com­pa­ny, $70M and a plan to leapfrog nat­ur­al killer com­peti­tors

5 years ago
Financing
Cell/Gene Tx

Yale spin­out re-en­gi­neers an im­munother­a­py GSK, oth­ers once aban­doned

5 years ago
Financing

A vir­tu­al biotech in­cu­ba­tor is launch­ing with the help of Evotec and Sam­sara, look­ing for a few good sci­en­tists in need of seed cash for spin­outs

5 years ago
Financing
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times